Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Details
Industries BiotechnologyLife ScienceTherapeuticsHeadquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date 2019 Founders Andrew Bell, Ed Tate, Roberto Solari Operating Status Active Last Funding Type Series A Also Known As Myricx Pharma Legal Name Myricx Pharma Ltd
Company Type For Profit
Myricx Bio is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyl transferase (NMT), primarily focusing on oncology and exploring potential applications across other diseases. NMT is an enzyme that modifies key proteins for cancer cell survival with specific lipids. Myricx Bio is
developing a pipeline of ADCs using its NMT inhibitor (NMTi) payload platform to address critical unmet needs in oncology. It shows excellent preclinical efficacy and safety across various solid tumor antigens and cancer cell types.
Products and Services
Product Name | Product Description |
---|---|